This study is evaluating efruxifermin in people with compensated cirrhosis (advanced scarring of the liver) caused by NASH (Nonalcoholic Steatohepatitis) or MASH (Metabolic Dysfunction-Associated Steatohepatitis). You may be able to join if you are between 18 and 80 years old and have biopsy-proven or non-invasively diagnosed compensated cirrhosis due to NASH/MASH. The study will compare efruxifermin to a placebo (an inactive substance) given by injection under the skin. Researchers want to see if efruxifermin can delay serious liver-related events over 5 years. For some participants, they will also look for improvement in liver scarring without worsening of steatohepatitis (liver inflammation and fat) after 96 weeks. The current recruitment status is unclear, but the study plans to enroll 2150 participants.

Study design

This is a randomized, double-blind, placebo-controlled study, meaning participants are randomly assigned to receive either efruxifermin or a placebo, and neither you nor your doctor will know which you are receiving. The study aims to enroll 2150 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 5 years to track significant clinical events. For some participants, liver changes will be assessed at 96 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.